

Filed: March 9, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

YEDA RESEARCH & DEVELOPMENT CO. LTD.

Patent Owner.

Case IPR2015-00644

Patent No. 8,399,413

MYLAN'S REPLY TO YEDA'S PATENT OWNER RESPONSE

TABLE OF CONTENTS

| | | |
|------|--|----|
| I. | The Prior Art Motivated Development of a Less Frequent Dosing Regimen | 3 |
| A. | POSAs Knew Less Frequent Dosing Would Improve Convenience | 3 |
| B. | POSAs Knew Less Frequent Dosing Would Increase Tolerability by Reducing ISRs | 4 |
| II. | A POSA Would Have Reasonably Expected a 40 mg TIW Regimen to Be Efficacious | 8 |
| A. | The Prior Art Suggested Less Frequent GA Administration Was Efficacious and Expressly Encouraged Pursuit of Such a Regimen | 8 |
| B. | The Claimed Regimen Falls Squarely Within a Known Range of Therapeutically Efficacious Doses | 9 |
| C. | The SBOA Pharmacokinetic Data Provide a Reasonable Expectation of Success | 14 |
| D. | Dr. Ziemssen’s Mechanism of Action Theory Does Not Teach Away From Less Frequent Than Daily Dosing | 16 |
| III. | All Dependent Claims Are Obvious | 18 |
| IV. | Patent Owner’s Secondary Considerations Cannot Save The Patent | 19 |
| A. | Patent Owner Has Not Established Any Unexpected Results | 19 |
| B. | The Established Copaxone [®] Brand and Steep Price Discounts Drove Copaxone [®] 40mg Sales, Not The Claimed Subject Matter | 20 |
| C. | The Patent Satisfied No Long-Felt But Unmet Need | 21 |

TABLE OF AUTHORITIES

CASES

| | |
|--|---------------|
| <i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013) | 9, 13, 21, 22 |
| <i>Hoffman-La Roche Inc. v. Apotex Inc.</i> , 748 F.3d 1326 (Fed. Cir. 2014) | 3, 10, 13 |
| <i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007)..... | 3 |
| <i>Merck & Co., Inc. v. Teva Pharms. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005) | 10 |
| <i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007) | 11 |
| <i>Teva Pharms. USA, Inc. v. Sandoz, Inc.</i> , 789 F.3d 1335 (Fed. Cir. 2015) | 21 |

TABLE OF ABBREVIATIONS

| ABBREVIATION | DESCRIPTION |
|----------------|---|
| CNS | Central nervous system |
| FDA | U.S. Food and Drug Administration |
| Fletcher 2002A | Shlomo Flechter et al., <i>Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternate-Day Administration</i> . 25:1 CLINICAL NEUROPHARMACOLOGY, 11-15 (2002) (Ex. 1008) |
| GA | Glatiramer acetate |
| IPIRs | Immediate post injection reactions |
| ISRs | Injection site reactions |
| MS | Multiple Sclerosis |
| Pinchasi | Irit Pinchasi: International Publication No. WO 2007/081975 (published July 19, 2007) (Ex. 1005) |
| POSA | Person of ordinary skill in the art |
| RRMS | Relapsing remitting multiple sclerosis |
| SBOA | Ex. 1007, Summary Basis of Approval for the New Drug Application for 20 mg daily Copaxone® (NDA #20-622). |
| Teva | Teva Pharmaceuticals Industries Ltd. is the exclusive licensee of the '250, '302, and '413 patents. Teva Pharmaceuticals USA, Inc. is the holder of the New Drug Application for Copaxone®, a drug for which the '250, '302, and '413 patents are listed in the FDA publication "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly referred to as "the Orange Book." Teva Neuroscience, Inc. markets and sells Copaxone® in the United States. |
| TIW | Three injections per week |
| Yeda | Yeda Research & Development Co. Ltd. |

All claims of the '413 patent are obvious based on Pinchasi in view of either (1) Flechter 2002A, or (2) the SBOA. Pinchasi disclosed administration of 40 mg of GA every other day, a regimen nearly identical to the claimed 40 mg TIW regimen. As Pinchasi is practically anticipatory, its combination with either Flechter 2002A or the SBOA easily shows obviousness. Patent Owner stakes its case on the untenable position that, despite its own disclosure of 40 mg every other day dosing in Pinchasi, the prior art teaches away from less frequent than daily dosing.

Patent Owner's position contradicts basic knowledge in the art and overwhelming clinical data. POSAs have long known that patients dislike Copaxone's daily injections, which cause ISRs, needle fatigue, and noncompliance. At least since an FDA reviewer in 1996 suggested less frequent GA administration as a possible solution (Ex. 1007), artisans have investigated lower frequency dosing, achieving promising results. Only Patent Owner's blocking patents on GA (and its manufacturing process) impeded earlier commercialization of the claimed regimen. As shown in the table below, by 2009, clinicians had amassed data that showed (1) every other day GA administration is as effective as daily administration (Ex. 1008, 1010, 1011), (2) 40 mg is a safe, efficacious, and well-tolerated dose (Ex. 1005, Ex. 1006), and (3) GA is efficacious in total weekly doses between 70 mg and 280 mg.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.